Catalyst Pharmaceuticals (CPRX) Work In Process (2023 - 2026)
Catalyst Pharmaceuticals' (CPRX) quarterly Work In Process came in at $2.8 million in Q1 2026, down 34.42% YoY from $4.2 million in Q1 2025, and down 28.44% on a QoQ basis from $3.9 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) Work In Process (2023 - 2026) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 4 years of Work In Process data on file, last reported at $2.8 million in Q1 2026.
- Quarterly Work In Process fell 34.42% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 34.42% YoY) and the FY2025 annual result came in at $3.9 million, up 12.37% from the prior year.
- Work In Process retreated to $2.8 million in Q1 2026, from $3.9 million in the prior quarter.
- In the past five years, Work In Process ranged from a high of $5.3 million in Q2 2025 to a low of $2.8 million in Q1 2026.
- A 4-year average of $4.1 million and a median of $4.0 million in 2024 frame the typical range for Work In Process.
- Annual changes were most pronounced in 2025 — Work In Process surged 32.89% — and 2026, when it sank 34.42%.
- Tracing CPRX's Work In Process over 4 years: stood at $4.6 million in 2023, then retreated by 24.67% to $3.4 million in 2024, then climbed by 12.37% to $3.9 million in 2025, then declined by 28.44% to $2.8 million in 2026.
- The last three Work In Process figures came in at $2.8 million (Q1 2026), $3.9 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.77 Mn |
| Dec 31, 2025 | 3.87 Mn |
| Sep 30, 2025 | 4.60 Mn |
| Jun 30, 2025 | 5.35 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 3.83 Mn |
| Jun 30, 2024 | 4.02 Mn |
| Dec 31, 2023 | 4.57 Mn |